Gene therapy of hemoglobinopathies: progress and future challenges
The DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.
Abstract
Recently, gene therapy clinical trials have been successfully applied to hemoglobinopathies, such as sickle cell disease (SCD) and β-thalassemia. Among the great discoveries that led to the design of genetic approaches to cure these disorders is the discovery of the β-globin locus control region and several associated transcription factors, which determine hemoglobin switching as well as high-level, erythroid-specific expression of genes at the ß-globin locus. Moreover, increasing evidence shows that lentiviral vectors are efficient tools to insert large DNA elements into nondividing hematopoietic stem cells, showing reassuring safe integration profiles. Alternatively, genome editing could restore expression of fetal hemoglobin or target specific mutations to restore expression of the wild-type β-globin gene. The most recent clinical trials for β-thalassemia and SCD are showing promising outcomes: patients were able to discontinue transfusions or had reduced transfusion requirements. However, toxic myeloablation and the high cost of current ex vivo hematopoietic stem cell gene therapy platforms represent a barrier to a widespread application of these approaches. In this review, we summarize these gene therapy strategies and ongoing clinical trials. Finally, we discuss possible strategies to improve outcomes, reduce myeloablative regimens and future challenges to reduce the cost of gene therapy platform.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inactivation and activation of genes within the b-globin gene cluster holds the keys to reactivating for therapeutic gain the usually dormant HbF genes.[6][7][8][9][10][11][12]”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [6]
Citations
Cites
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276
Self-citationGene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
Pathogenesis and Treatment of Sickle Cell Disease
Bunn, H. F. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371107 · Cited by 1,154
Kay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022 · cited 1×
“In this respect, several pseudotyping envelopes (72) or different type of viral vectors [foamy virus (73,74) or adenoassociated viral vectors (75)] have emerged in the field.”
BackgroundHuman Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-Specific Repressor BCL11A
Sankaran, V. G., Menne, T. F., Xu, J., Akie, T. E., Lettre, G., Van Handel, B., Mikkola, H. K. A., Hirschhorn, J. N., Cantor, A. B., & Orkin, S. H. (2008) · Science · doi:10.1126/science.1165409 · Cited by 919
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis
Canver, M. C., Smith, E. C., Sher, F., Pinello, L., Sanjana, N. E., Shalem, O., Chen, D. D., Schupp, P. G., Vinjamur, D. S., Garcia, S. P., et al. (2015) · Nature · doi:10.1038/nature15521 · Cited by 886 · cited 1×
“red cells resulting in elevated HbF level (46,47).”
BackgroundGene therapy in a patient with sickle cell disease
Ribeil, J.-A., Hacein-Bey-Abina, S., Payen, E., Magnani, A., Semeraro, M., Magrin, E., Caccavelli, L., Neven, B., Bourget, P., El Nemer, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609677 · Cited by 696 · cited 1×
“A first patient treated in France with the BB305 LV rapidly achieved a level of therapeutic anti-sickling globin (HbAT87Q) of ∼50% with clinical and biological parameters typical of SCD carriers (18).”
BackgroundSelf-citationGene Therapy in Patients with Transfusion-Dependent β-Thalassemia
Thompson, A. A., Walters, M. C., Kwiatkowski, J., Rasko, J. E. J., Ribeil, J.-A., Hongeng, S., Magrin, E., Schiller, G. J., Payen, E., Semeraro, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705342 · Cited by 684
Self-citationUda, M., Galanello, R., Sanna, S., Lettre, G., Sankaran, V. G., Chen, W., Usala, G., Busonero, F., Maschio, A., Albai, G., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711566105 · Cited by 672
An Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level
Bauer, D. E., Kamran, S. C., Lessard, S., Xu, J., Fujiwara, Y., Lin, C., Shao, Z., Canver, M. C., Smith, E. C., Pinello, L., et al. (2013) · Science · doi:10.1126/science.1242088 · Cited by 653 · cited 1×
“The B cell CLL/lymphoma 11A (BCL11A) protein is a major modulator of HbF expression (36,37), and genetic variation in the erythroid enhancer of BCL11A affects its expression and, consequently, HbF levels (38).”
BackgroundThe "beta-like-globin" gene domain in human erythroid cells.
Tuan, D., Solomon, W., Li, Q., & London, I. M. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.19.6384 · Cited by 601 · cited 1×
“Although the combination of a full LCR and an adult β-globin gene, including its introns and 3′ untranslated regions, has showed satisfactory levels of gene expression (15) , the full LCR is too large to fit into a lentiviral vector (LV) construct (16).”
BackgroundCorrection of sickle cell disease in transgenic mouse models by gene therapy
Pawliuk, R., Westerman, K. A., Fabry, M. E., Payen, E., Tighe, R., Bouhassira, E. E., Acharya, S. A., Ellis, J., London, I. M., Eaves, C. J., et al. (2001) · Science · doi:10.1126/science.1065806 · Cited by 579 · cited 2×
“globin) at much higher levels proved efficacious in correcting two mouse models of β-thalassemia (28,30,31) and SCD (29), paving the way to clinical trials.”
BackgroundMay, C., Rivella, S., Callegari, J., Heller, G., Gaensler, K. M. L., Luzzatto, L., & Sadelain, M. (2000) · Nature · doi:10.1038/35017565 · Cited by 567
Self-citationA QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15
Menzel, S., Garner, C., Gut, I., Matsuda, F., Yamaguchi, M., Heath, S., Foglio, M., Zelenika, D., Boland, A., Rooks, H., et al. (2007) · Nature Genetics · doi:10.1038/ng2108 · Cited by 529 · cited 1×
“The B cell CLL/lymphoma 11A (BCL11A) protein is a major modulator of HbF expression (36,37), and genetic variation in the erythroid enhancer of BCL11A affects its expression and, consequently, HbF levels (38).”
BackgroundHighly efficient therapeutic gene editing of human hematopoietic stem cells
Wu, Y., Zeng, J., Roscoe, B. P., Liu, P., Yao, Q., Lazzarotto, C. R., Clement, K., Cole, M. A., Luk, K., Baricordi, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0401-y · Cited by 515 · cited 1×
“treatment options for hemoglobinopathies (49).”
Bolaños-Meade, J., Fuchs, E. J., Luznik, L., Lanzkron, S. M., Gamper, C. J., Jones, R. J., & Brodsky, R. A. (2012) · Blood · doi:10.1182/blood-2012-07-438408 · Cited by 444
Disorders of hemoglobin genetics, pathophysiology, and clinical management
Steinberg, M. H. (2001) · Cited by 438
Efficient Transplantation via Antibody-Based Clearance of Hematopoietic Stem Cell Niches
Czechowicz, A., Kraft, D., Weissman, I. L., & Bhattacharya, D. (2007) · Science · doi:10.1126/science.1149726 · Cited by 432
Bcl11a is essential for normal lymphoid development
Liu, P., Keller, J. R., Ortiz, M., Tessarollo, L., Rachel, R. A., Nakamura, T., Jenkins, N. A., & Copeland, N. G. (2003) · Nature Immunology · doi:10.1038/ni925 · Cited by 351
Dzierzak, E. A., Papayannopoulou, T., & Mulligan, R. C. (1988) · Nature · doi:10.1038/331035a0 · Cited by 338
Hot spots of retroviral integration in human CD34+ hematopoietic cells
Cattoglio, C., Facchini, G., Sartori, D., Antonelli, A., Miccio, A., Cassani, B., Schmidt, M., von Kalle, C., Howe, S., Thrasher, A. J., et al. (2007) · Blood · doi:10.1182/blood-2007-01-068759 · Cited by 270 · cited 1×
“In addition, editing approaches could be theoretically safer compared to LVs integrating semi-randomly in the genome (50,51).”
MethodSelf-citationLentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1
Mamcarz, E., Zhou, S., Lockey, T., Abdelsamed, H., Cross, S. J., Kang, G., Ma, Z., Condori, J., Dowdy, J., Triplett, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815408 · Cited by 263 · cited 1×
“Recently, one stable producer cell line has been described for a SCID-X1 lentiviralbased gene therapy trial (64) and if available, it should represent another step forward to reduce the cost of these viral preparations.”
BackgroundLocatelli, F., Kabbara, N., Ruggeri, A., Ghavamzadeh, A., Roberts, I., Li, C. K., Bernaudin, F., Vermylen, C., Dalle, J.-H., Stein, J., et al. (2013) · Blood · doi:10.1182/blood-2013-03-489112 · Cited by 244 · cited 1×
“potential morbidity and mortality especially when realized from a donor other than an HLA-identical sibling and in adults affected by severe organ damage (3,4).”
BackgroundMarktel, S., Scaramuzza, S., Cicalese, M. P., Giglio, F., Galimberti, S., Lidonnici, M. R., Calbi, V., Assanelli, A., Bernardo, M. E., Rossi, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0301-6 · Cited by 225
Rivella, S., May, C., Chadburn, A., Rivière, I., & Sadelain, M. (2003) · Blood · doi:10.1182/blood-2002-10-3305 · Cited by 220
Self-citationPerrine, R. P., Brown, M. J., Clegg, J. B., Weatherall, D. J., & May, A. (1972) · The Lancet · doi:10.1016/s0140-6736(72)92592-5 · Cited by 220
Palchaudhuri, R., Saez, B., Hoggatt, J., Schajnovitz, A., Sykes, D. B., Tate, T. A., Czechowicz, A., Kfoury, Y., Ruchika, F., Rossi, D. J., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3584 · Cited by 217 · cited 1×
“An antibody that recognizes mouse and human CD45, when coupled to the toxin saponin (CD45-SAP), enables long-term engraftment of syngeneic cells, while minimizing the cytopenia and immunosuppression due to toxic conditioning (67).”
BackgroundTranscriptional regulation of fetal to adult hemoglobin switching: new therapeutic opportunities
Wilber, A., Nienhuis, A. W., & Persons, D. A. (2011) · Blood · doi:10.1182/blood-2010-11-316893 · Cited by 215 · cited 9×
“The LCR is composed of multiple hypersensitivity sites (HS1, HS2, HS3, HS4 and HS5) with high affinity for transcription factors.”
BackgroundInfluentialLuxturna: FDA documents reveal the value of a costly gene therapy
Darrow, J. J. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.01.019 · Cited by 213
Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges
Cavazzana, M., Bushman, F. D., Miccio, A., André-Schmutz, I., & Six, E. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0020-9 · Cited by 199 · cited 1×
“These trials provided strong evidence of clinical long-term efficacy in the absence of genotoxicity (12).”
BackgroundSelf-citationRussell, D. W., & Miller, A. D. (1996) · Journal of Virology · doi:10.1128/jvi.70.1.217-222.1996 · Cited by 174 · cited 1×
“In this respect, several pseudotyping envelopes (72) or different type of viral vectors [foamy virus (73,74) or adenoassociated viral vectors (75)] have emerged in the field.”
BackgroundHematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy
Chhabra, A., Ring, A. M., Weiskopf, K., Schnorr, P. J., Gordon, S., Le, A. C., Kwon, H.-S., Ring, N. G., Volkmer, J., Ho, P. Y., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aae0501 · Cited by 172 · cited 1×
“Targeting CD117 enables autologous engraftment in immunodeficient mice (68), and when coupled with CD47 blockade enables engraftment in immunocompetent mice (69).”
BackgroundLineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype.
Brendel, C., Guda, S., Renella, R., Bauer, D. E., Canver, M. C., Kim, Y.-J., Heeney, M. M., Klatt, D., Fogel, J., Milsom, M. D., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87885 · Cited by 167 · cited 1×
“In a current open gene therapy trial (NCT03282656, Table 1), the HbF induction strategy is based on introduction of shRNA targeting BCL11A suppression in erythroid cells derived from HSCs for the purpose of increasing γ-globin and reducing mutant βS globin expression (58).”
Backgroundde la Fuente, J., Dhedin, N., Koyama, T., Bernaudin, F., Kuentz, M., Karnik, L., Socié, G., Culos, K. A., Brodsky, R. A., DeBaun, M. R., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.11.027 · Cited by 166
Successful treatment of murine β-thalassemia intermedia by transfer of the human β-globin gene
May, C., Rivella, S., Chadburn, A., & Sadelain, M. (2002) · Blood · doi:10.1182/blood.v99.6.1902 · Cited by 164
Self-citationChang, K.-H., Smith, S. E., Sullivan, T., Chen, K., Zhou, Q., West, J. A., Liu, M., Liu, Y., Vieira, B. F., Sun, C., et al. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2016.12.009 · Cited by 155
Zonari, E., Desantis, G., Petrillo, C., Boccalatte, F. E., Lidonnici, M. R., Kajaste-Rudnitski, A., Aiuti, A., Ferrari, G., Naldini, L., & Gentner, B. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.02.010 · Cited by 152
Cone, R. D., Weber-Benarous, A., Baorto, D., & Mulligan, R. C. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.2.887 · Cited by 151
Dendritic cell fate is determined by BCL11A
Ippolito, G. C., Dekker, J. D., Wang, Y.-H., Lee, B.-K., Shaffer, A. L., Lin, J., Wall, J. K., Lee, B.-S., Staudt, L. M., Liu, Y.-J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319228111 · Cited by 128
Novak, U., Harris, E. A., Forrester, W., Groudine, M., & Gelinas, R. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.9.3386 · Cited by 127
miRNA-embedded shRNAs for Lineage-specific BCL11A Knockdown and Hemoglobin F Induction
Guda, S., Brendel, C., Renella, R., Du, P., Bauer, D. E., Canver, M. C., Grenier, J. K., Grimson, A. W., Kamran, S. C., Thornton, J., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.113 · Cited by 123 · cited 1×
“Initial studies showed that knockdown of BCL11A using an LV shRNA/miRNA approach causes induction of HbF in human erythroid cells (44,45).”
MethodBcl11a Deficiency Leads to Hematopoietic Stem Cell Defects with an Aging-like Phenotype
Luc, S., Huang, J., McEldoon, J. L., Somuncular, E., Li, D., Rhodes, C., Mamoor, S., Hou, S., Xu, J., & Orkin, S. H. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.064 · Cited by 122
Lagresle-Peyrou, C., Lefrère, F., Magrin, E., Ribeil, J.-A., Romano, O., Weber, L., Magnani, A., Sadek, H., Plantier, C., Gabrion, A., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.184788 · Cited by 117 · cited 1×
“Furthermore, to obtain a high cell number, HSCs from SCD patients have to be mobilized in the peripheral blood by plerixafor under controlled conditions (56).”
Self-citationTreating Immunodeficiency through HSC Gene Therapy
Booth, C., Gaspar, H. B., & Thrasher, A. J. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.02.002 · Cited by 116 · cited 1×
“adrenoleukodystrophy or metachromatic leukodystrophy), to name a few (10,11).”
BackgroundPsatha, N., Reik, A., Phelps, S., Zhou, Y., Dalas, D., Yannaki, E., Levasseur, D. N., Urnov, F. D., Holmes, M. C., & Papayannopoulou, T. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.08.003 · Cited by 115
Karlsson, S., Bodine, D. M., Perry, L., Papayannopoulou, T., & Nienhuis, A. W. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.16.6062 · Cited by 114
Anurathapan, U., Hongeng, S., Pakakasama, S., Sirachainan, N., Songdej, D., Chuansumrit, A., Charoenkwan, P., Jetsrisuparb, A., Sanpakit, K., Rujkijyanont, P., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.7 · Cited by 110
Tsang, J. C. H., Yu, Y., Burke, S., Buettner, F., Wang, C., Kolodziejczyk, A. A., Teichmann, S. A., Lu, L., & Liu, P. (2015) · Genome Biology · doi:10.1186/s13059-015-0739-5 · Cited by 109
$1-million price tag set for Glybera gene therapy
Morrison, C. (2015) · Nature Biotechnology · doi:10.1038/nbt0315-217 · Cited by 107
Haploidentical HSCT for hemoglobinopathies: improved outcomes with TCRαβ+/CD19+-depleted grafts
Gaziev, J., Isgrò, A., Sodani, P., Paciaroni, K., Angelis, G. D., Marziali, M., Ribersani, M., Alfieri, C., Lanti, A., Galluccio, T., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017012005 · Cited by 93
Wang, C. X., Sather, B. D., Wang, X., Adair, J., Khan, I., Singh, S., Lang, S., Adams, A., Curinga, G., Kiem, H.-P., et al. (2014) · Blood · doi:10.1182/blood-2013-12-546218 · Cited by 88
Pseudotyped Lentiviral Vectors: One Vector, Many Guises
Joglekar, A. V., & Sandoval, S. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2017.084 · Cited by 87
Breda, L., Casu, C., Gardenghi, S., Bianchi, N., Cartegni, L., Narla, M., Yazdanbakhsh, K., Musso, M., Manwani, D., Little, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032345 · Cited by 83
Self-citationWang, X., Shin, S. C., Chiang, A. F. J., Khan, I., Pan, D., Rawlings, D. J., & Miao, C. H. (2015) · Molecular Therapy · doi:10.1038/mt.2015.20 · Cited by 80 · cited 1×
“(70) reported that a single intraosseous infusion of LVs to hemophilia D ow naded rom http/academ ic.”
BackgroundHeffner, G. C., Bonner, M., Christiansen, L., Pierciey, F. J., Campbell, D., Smurnyy, Y., Zhang, W., Hamel, A., Shaw, S., Lewis, G., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.025 · Cited by 72
Funnell, A. P. W., Prontera, P., Ottaviani, V., Piccione, M., Giambona, A., Maggio, A., Ciaffoni, F., Stehling-Sun, S., Marra, M., Masiello, F., et al. (2015) · Blood · doi:10.1182/blood-2015-04-638528 · Cited by 70 · cited 1×
“Patients with BCL11A haploinsufficiency have increased levels of HbF at levels likely to be therapeutic for patients with β-hemoglobinopathies (39).”
BackgroundHematopoietic stem cell transplantation for sickle cell disease: Progress and challenges
Hulbert, M. L., & Shenoy, S. S. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27263 · Cited by 57 · cited 1×
“potential morbidity and mortality especially when realized from a donor other than an HLA-identical sibling and in adults affected by severe organ damage (3,4).”
BackgroundPetrillo, C., Cesana, D., Piras, F., Bartolaccini, S., Naldini, L., Montini, E., & Kajaste-Rudnitski, A. (2015) · Molecular Therapy · doi:10.1038/mt.2014.193 · Cited by 56
T Cell-Depleted HlA-Haploidentical Stem Cell Transplantation in Thalassemia Young Patients
Sodani, P., Isgrò, A., Gaziev, J., Paciaroni, K., Marziali, M., Simone, M. D., Roveda, A., Alfieri, C., Angelis, G. D., Gallucci, C., et al. (2011) · Pediatric Reports · doi:10.4081/pr.2011.s2.e13 · Cited by 49
Gene regulation and deregulation: a β globin perspective
Ho, P. J., & Thein, S. L. (2000) · Blood Reviews · doi:10.1054/blre.2000.0128 · Cited by 48
Allewelt, H. B., El-Khorazaty, J. A., Mendizabal, A. M., Taskindoust, M., Martin, P., Prasad, V. K., Page, K. M., Sanders, J. E., & Kurtzberg, J. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.05.024 · Cited by 47 · cited 1×
“These regimens appear to carry risks of both early transplant-associated toxicity as well as late effects like infertility and secondary malignancies (66).”
BackgroundHemoglobin genetics: recent contributions of GWAS and gene editing
Smith, E. C., & Orkin, S. H. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw170 · Cited by 45 · cited 9×
“The LCR is composed of multiple hypersensitivity sites (HS1, HS2, HS3, HS4 and HS5) with high affinity for transcription factors.”
BackgroundInfluentialIntravenous injection of a foamy virus vector to correct canine SCID-X1
Burtner, C. R., Beard, B. C., Kennedy, D. R., Wohlfahrt, M. E., Adair, J. E., Trobridge, G. D., Scharenberg, A. M., Torgerson, T. R., Rawlings, D. J., Felsburg, P. J., et al. (2014) · Blood · doi:10.1182/blood-2013-11-538926 · Cited by 41 · cited 1×
“In this respect, several pseudotyping envelopes (72) or different type of viral vectors [foamy virus (73,74) or adenoassociated viral vectors (75)] have emerged in the field.”
BackgroundWada‐Kiyama, Y., & Kiyama, R. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31782-9 · Cited by 34
In Vivo Gene Delivery into hCD34+ Cells in a Humanized Mouse Model
Frecha, C. A., Fusil, F., Cosset, F., & Verhoeyen, E. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-095-9_15 · Cited by 30
Malik, P., Grimley, M. S., Quinn, C. T., Shova, A., Little, C., Lutzko, C., Kalfa, T. A., Niss, O., Mehta, P. A., Chandra, S., et al. (2018) · Blood · doi:10.1182/blood-2018-99-119591 · Cited by 27 · cited 1×
“(57) treated two βS/β0 patients after a reduced intensity conditioning regimen using an LV expressing a modified γ-globin transgene (NCT02186418, Table 1); the LVinduced HbF accounted for ∼20% to 30% of the total Hb and the patients displayed a significant improvement in clinical and biological parameters; the favorab…”
MethodTisdale, J. F., Kanter, J., Mapara, M. Y., Kwiatkowski, J. L., Krishnamurti, L., Schmidt, M., Miller, A. L., Pierciey, F. J., Shi, W., Ribeil, J., et al. (2018) · Blood · doi:10.1182/blood-2018-99-113480 · Cited by 26 · cited 2×
“hematopoietic/stem progenitor cells and transduction protocol [NCT02140554/HGB206 (54,55), Table 1].”
BackgroundSelf-citationGene Addition Strategies for β-Thalassemia and Sickle Cell Anemia
Dong, A., & Rivella, S. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-7299-9_6 · Cited by 21
Self-citationEsrick, E. B., Brendel, C., Manis, J. P., Armant, M. A., Trebeden‐Negre, H., Dansereau, C., Ciuculescu, M. F., Patriarca, S., Mackinnon, B., Daley, H., et al. (2018) · Blood · doi:10.1182/blood-2018-99-116733 · Cited by 17 · cited 1×
“anti-sickling hemoglobin/per cell are two key criteria to obtain clinical benefit (59).”
BackgroundOutcomes for Initial Patient Cohorts with up to 33 Months of Follow-up in the Hgb-206 Phase 1 Trial
Kanter, J., Tisdale, J. F., Kwiatkowski, J. L., Krishnamurti, L., Mapara, M. Y., Schmidt, M., Miller, A. L., Pierciey, F. J., Shi, W., Ribeil, J., et al. (2018) · Blood · doi:10.1182/blood-2018-99-113477 · Cited by 15 · cited 1×
“hematopoietic/stem progenitor cells and transduction protocol [NCT02140554/HGB206 (54,55), Table 1].”
BackgroundSelf-citationHLA-Mismatched Hematopoietic Stem Cell Tranplantation for Pediatric Solid Tumors
Pession, A., Masetti, R., Leo, C. D., Franzoni, M., & Prete, A. (2011) · Pediatric Reports · doi:10.4081/pr.2011.s2.e12 · Cited by 12
Opening Marrow Niches in Patients Undergoing Autologous Hematopoietic Stem Cell Gene Therapy
Cowan, M. J., Dvorak, C. C., & Long-Boyle, J. R. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.003 · Cited by 8 · cited 1×
“Successful gene therapy trials have generally utilized myeloablative doses of busulfan around 12– 16 mg/kg (65).”
Background
Research works printed but not linked: 2
- Patel, 2016, CADTH Issues in Emerging Health Technologies
- Rasko, 2018, American Society of Hematology. American Society of Hematology, 132
Cited by
Piel, F. B., Rees, D. C., DeBaun, M. R., Nnodu, O., Ranque, B., Thompson, A. A., Ware, R. E., Abboud, M. R., Abraham, A., Ambrose, E. E., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00096-0 · Cited by 177
Lattanzi, A., Camarena, J., Lahiri, P., Segal, H., Srifa, W., Vakulskas, C. A., Frock, R. L., Kenrick, J., Lee, C., Talbott, N., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf2444 · Cited by 167
Fetal hemoglobin in sickle cell anemia
Steinberg, M. H. (2020) · Blood · doi:10.1182/blood.2020007645 · Cited by 136
Gutiérrez-Guerrero, A., Cosset, F., & Verhoeyen, E. (2020) · Viruses · doi:10.3390/v12091016 · Cited by 131
“In the last couple of decades, these improvements have given way to various numbers of successful clinical trials in diverse monogenic diseases, such as severe combined immunodeficiencies (SCID) and β-hemoglobinopathies [76,77], which today resulted in two dozen gene therapies, clinically approved as drugs [78].”
BackgroundPrinciples of Genomic Newborn Screening Programs: A Systematic Review
Downie, L., Halliday, J. L., Lewis, S., & Amor, D. J. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.14336 · Cited by 121
Metadata
- Authors
- Ikawa, Y., Miccio, A., Magrin, E., Kwiatkowski, J. L., Rivella, S., & Cavazzana, M.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Inserm (FR)
- Hôpital Necker-Enfants Malades (FR)
- Corresponding author
- Rivella, Stefano
- ORCID
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-07-19
- Volume
- 28
- Issue
- R1
- Pages
- R24-R30
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2964149073
- Cited by
- 86
- References
- 75
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 7 · 2023: 7 · 2022: 6 · 2021: 21 · 2020: 31 · 2019: 2
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Human Molecular Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-10-IAHU-01, ANR-16-CE18-0004)
- European Union’s Horizon 2020 (693762-ERC-2015-AdG- GENEFORCURE)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- gene therapy, hemoglobinopathies, sickle cell disease, beta-thalassemia, beta-globin locus control region, hemoglobin switching, lentiviral vectors, hematopoietic stem cells, genome editing, fetal hemoglobin, myeloablation, ex vivo gene therapy, clinical trials, cost of gene therapy
- MeSH terms
- Animals, Clinical Trials as Topic, Gene Expression Regulation, Genetic Vectors, Hemoglobinopathies, Hemoglobins, Humans, Mutation, Transduction, Genetic, Genetic Therapy, Treatment Outcome, Hematopoietic Stem Cell Transplantation, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.